Pramipexole News and Research

RSS

Groundbreaking study reveals most effective adjunctive drug for Parkinson's disease

The efficacy, tolerability, and safety of various anti-Parkinson's drugs.

23 Oct 2023

Parkinson's disease diagnosed after SARS-CoV-2

As the COVID-19 pandemic continues to spread, new and unusual chronic sequelae of the disease are cropping up in many medical practices. Now, a new case paper published in The Lancet in September 2020 describes a case of new-onset Parkinson's disease following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Sep 2020

Increase in out-of-pocket costs associated with lower adherence to neurologic medications

As out-of-pocket costs go up for drugs for the neurologic disorders Alzheimer's disease, peripheral neuropathy and Parkinson's disease, people are less likely to take the drugs as often as their doctors prescribed, according to a study funded by the American Academy of Neurology and published in the February 19, 2020, online issue of Neurology, the medical journal of the American Academy of Neurology.

19 Feb 2020

New study supports motor cortex 'excitability' as cause of restless legs syndrome

Johns Hopkins Medicine researchers say new experiments using magnetic pulse brain stimulation on people with moderate to severe restless legs syndrome have added to evidence that the condition is due to excitability and hyperarousal in the part of the brain's motor cortex responsible for leg movement.

29 Aug 2018

Impulse control disorders found to be more common in people taking Parkinson's drugs

Over time, half of the people taking certain drugs for Parkinson's disease may develop impulse control disorders such as compulsive gambling, shopping or eating, according to a study published in the June 20, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology.

20 Jun 2018

Parkinson's disease medications could lead to impulse control disorders

Drugs commonly prescribed to treat Parkinson's disease have been linked to impulse control disorders such as pathological gambling, compulsive buying, hypersexuality and binge eating in some patients, report neurologists from Loyola Medicine and Loyola University Chicago Stritch School of Medicine.

6 Apr 2016

New treatment strategy may take pain away

A brain region controlling whether we feel happy or sad, as well as addiction, is remodeled by chronic pain, reports a new Northwestern Medicine study.

22 Dec 2015

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company's Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease (PD).

30 Jun 2015

Non-ergot derived dopamine agonists may be safe for the heart

Non-ergot derived dopamine agonists used to treat Parkinson's disease may be safe for the heart, according to preliminary research presented at EuroEcho-Imaging 2014 by Dr Hilal Erken Pamukcu, cardiologist at Ankara Diskapi Education and Research Hospital in Turkey.

4 Dec 2014

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

A report in the Feb. 13 New England Journal of Medicine confirms previous studies suggesting that long-term treatment with the type of drugs commonly prescribed to treat restless leg syndrome (RLS) can cause a serious worsening of the condition in some patients.

14 Feb 2014

Parkinson's disease drugs may lead to impulse control disorders

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients.

25 Mar 2011

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients.

24 Mar 2011

Mylan receives final FDA approval for Pramipexole Dihydrochloride Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg, the generic version of Boehringer Ingelheim's Mirapex Tablets, a Parkinson's disease treatment.

21 Oct 2010

Study suggests treating RLS may improve sleep and quality of life in people with fibromyalgia

A study in the Oct. 15, 2010 issue of the Journal of Clinical Sleep Medicine found that adults with fibromyalgia had a much higher prevalence and risk of restless legs syndrome than healthy controls. The study suggests that treating RLS may improve sleep and quality of life in people with fibromyalgia.

15 Oct 2010

Teva second-quarter net sales increase 12% to $3.8 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2010.

27 Jul 2010

NIH issues SBIR grant to Titan Pharmaceutical for PD treatment development

Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health has awarded the company a grant under the Small Business Innovation Research program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an additional $195,000 for the second year starting August 1, 2011 has been recommended subject to availability of funds and satisfactory progress of the project. The grant will be administered by the National Institute of Neurological Disorders and Stroke.

27 Jul 2010

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

9 Jul 2010

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended March 31, 2010.

4 May 2010

Pramipexole ER uptake to be inhibited by availability of generic version

HealthLeaders-InterStudy and Fingertip Formulary find that the uptake of Boehringer Ingelheim's pramipexole ER, the once-daily formulation of its market leading dopamine agonist Mirapex that was approved earlier this month, will be inhibited by competition from generic pramipexole which became available earlier this year.

1 Apr 2010

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease, which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure.

26 Mar 2010